CD274 and metastatic colorectal cancer: Several clinical trials are underway to investigate the effectiveness of anti‐PD‐L1 immunotherapy in combination with standard therapeutic regimens [e.g., chemotherapy (FOLFOX or FOLFOXIRI) plus bevacizumab] in metastatic colorectal cancer.42